Literature DB >> 24162875

Measuring health-related quality of life in high-grade glioma patients at the end of life using a proxy-reported retrospective questionnaire.

Eefje M Sizoo1, Linda Dirven, Jaap C Reijneveld, Tjeerd J Postma, Jan J Heimans, Luc Deliens, H Roeline W Pasman, Martin J B Taphoorn.   

Abstract

To develop, validate, and report on the use of a retrospective proxy-reported questionnaire measuring health-related quality of life (HRQoL) in the end-of-life (EOL) phase of high-grade glioma (HGG) patients. Items relevant for the defined construct were selected using existing questionnaires, topics identified as important in literature, and expert opinion (experienced neuro-oncologists and EOL experts). Psychometric properties, content validity and internal consistency, were determined and the questionnaire was subsequently adapted. Proxy-reported HRQoL data of HGG patients in the EOL, including changes over time, were analyzed. Twenty-nine items were selected covering seven domains; physical comfort, physical and cognitive functioning, psychological, social and spiritual well-being, and overall quality of life. Relatives of 83 deceased HGG patients completed the questionnaire. Content validity was assessed to be adequate. Internal consistency in the domains varied from reasonable to good. Two items were excluded due to poor psychometric properties. Symptom burden increased (p < 0.01), except for nausea (p = 0.058), as death approached. Cognitive, physical and psychological functioning deteriorated over time (all p < 0.01). Acceptance of disease seemed to increase slightly towards death, but this was not significant (p = 0.058). Participating in social activities and family life was rated as poor (≤ 50), whereas received support from their social environment and dying with dignity were rated as good (>50). Overall quality of life was rated as poor, mean (SD) of 29 (26). Measuring HRQoL at the EOL of HGG patients with a retrospective, proxy-reported questionnaire was feasible, yielding a validated instrument. HRQoL was reported as poor and deteriorated as death approached.

Entities:  

Mesh:

Year:  2013        PMID: 24162875     DOI: 10.1007/s11060-013-1289-x

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  38 in total

1.  How do patients with primary brain tumours die?

Authors:  C Bausewein; P Hau; G D I Borasio; R Voltz
Journal:  Palliat Med       Date:  2003-09       Impact factor: 4.762

2.  The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires.

Authors:  D Osoba; N K Aaronson; M Muller; K Sneeuw; M A Hsu; W K Yung; M Brada; E Newlands
Journal:  Qual Life Res       Date:  1996-02       Impact factor: 4.147

3.  The end-of-life hospital setting in patients with glioblastoma.

Authors:  Stefan Oberndorfer; Elisabeth Lindeck-Pozza; Heinz Lahrmann; Walter Struhal; Peter Hitzenberger; Wolfgang Grisold
Journal:  J Palliat Med       Date:  2008 Jan-Feb       Impact factor: 2.947

4.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

5.  Validity of the McGill Quality of Life Questionnaire in the palliative care setting: a multi-centre Canadian study demonstrating the importance of the existential domain.

Authors:  S R Cohen; B M Mount; E Bruera; M Provost; J Rowe; K Tong
Journal:  Palliat Med       Date:  1997-01       Impact factor: 4.762

Review 6.  Quality of life: what is it? How should it be measured?

Authors:  N K Aaronson
Journal:  Oncology (Williston Park)       Date:  1988-05       Impact factor: 2.990

7.  Decision-making in the end-of-life phase of high-grade glioma patients.

Authors:  Eefje M Sizoo; H Roeline W Pasman; Janine Buttolo; Jan J Heimans; Martin Klein; Luc Deliens; Jaap C Reijneveld; Martin J B Taphoorn
Journal:  Eur J Cancer       Date:  2011-12-05       Impact factor: 9.162

8.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.

Authors:  N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes
Journal:  J Natl Cancer Inst       Date:  1993-03-03       Impact factor: 13.506

Review 9.  Primary brain tumours in adults.

Authors:  Anthony Behin; Khe Hoang-Xuan; Antoine F Carpentier; Jean-Yves Delattre
Journal:  Lancet       Date:  2003-01-25       Impact factor: 79.321

10.  Epilepsy in the end-of-life phase in patients with high-grade gliomas.

Authors:  Andrea Pace; Veronica Villani; Cherubino Di Lorenzo; Lara Guariglia; Marta Maschio; Alfredo Pompili; Carmine Maria Carapella
Journal:  J Neurooncol       Date:  2012-10-20       Impact factor: 4.130

View more
  12 in total

1.  Symptoms and medication management in the end of life phase of high-grade glioma patients.

Authors:  J A F Koekkoek; L Dirven; E M Sizoo; H R W Pasman; J J Heimans; T J Postma; L Deliens; R Grant; S McNamara; G Stockhammer; E Medicus; M J B Taphoorn; J C Reijneveld
Journal:  J Neurooncol       Date:  2014-08-24       Impact factor: 4.130

Review 2.  Life beyond a diagnosis of glioblastoma: a systematic review of the literature.

Authors:  L Gately; S A McLachlan; A Dowling; J Philip
Journal:  J Cancer Surviv       Date:  2017-02-13       Impact factor: 4.442

3.  Validating self-report and proxy reports of the Dexamethasone Symptom Questionnaire -Chronic for the evaluation of longer-term corticosteroid toxicity.

Authors:  Meera Agar; Eng-Siew Koh; Emma Gibbs; Elizabeth H Barnes; Elizabeth Hovey; Ann Livingstone; Kate Sawkins; Richard Chye; Melanie R Lovell; Katherine Clark; Janette Vardy; Madeleine King
Journal:  Support Care Cancer       Date:  2015-08-21       Impact factor: 3.603

4.  Walking ability in patients with glioblastoma: prognostic value of the Berg Balance Scale and the 10 meter walk test.

Authors:  Monique Mesot Liljehult; Lise Buus; Jacob Liljehult; Birthe Krogh Rasmussen
Journal:  J Neurooncol       Date:  2017-07-27       Impact factor: 4.130

Review 5.  Living longer with adult high-grade glioma: setting a research agenda for patients and their caregivers.

Authors:  Bethany Russell; Anna Collins; Michael Dally; Anthony Dowling; Michelle Gold; Michael Murphy; Jennifer Philip
Journal:  J Neurooncol       Date:  2014-07-01       Impact factor: 4.130

6.  Comparison of the quality of death between primary malignant brain tumor patients and other cancer patients: results from a nationwide bereavement survey in Japan.

Authors:  Maho Aoyama; Kento Masukawa; Ikuko Sugiyama; Tatsuya Morita; Yoshiyuki Kizawa; Satoru Tsuneto; Yasuo Shima; Mitsunori Miyashita
Journal:  J Neurooncol       Date:  2022-04-18       Impact factor: 4.130

7.  Long-term survivors of glioblastoma: a closer look.

Authors:  Lucy Gately; Sue-Anne McLachlan; Jennifer Philip; Jeremy Ruben; Anthony Dowling
Journal:  J Neurooncol       Date:  2017-10-27       Impact factor: 4.130

8.  Compliance with patient-reported outcome assessment in glioma patients: predictors for drop out.

Authors:  Mirjam Renovanz; Marlene Hechtner; Karoline Kohlmann; Mareile Janko; Minou Nadji-Ohl; Susanne Singer; Florian Ringel; Jan Coburger; Anne-Katrin Hickmann
Journal:  Neurooncol Pract       Date:  2017-10-31

Review 9.  Management of Gliomas: Overview of the Latest Technological Advancements and Related Behavioral Drawbacks.

Authors:  L Ganau; M Paris; G K Ligarotti; M Ganau
Journal:  Behav Neurol       Date:  2015-08-09       Impact factor: 3.342

10.  The characteristics of patients who discontinue their dying process - an observational study at a single university hospital centre.

Authors:  Christian Schulz; Daniel Schlieper; Christiane Altreuther; Manuela Schallenburger; Katharina Fetz; Andrea Schmitz
Journal:  BMC Palliat Care       Date:  2015-12-07       Impact factor: 3.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.